Omid Hamid
Advanced in Metastatic Brain Tumor

Dr. Omid Hamid

Hematology | Oncology
Cedars-Sinai Medical Care Foundation
8700 Beverly Blvd, 
West Hollywood, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Advanced in Metastatic Brain Tumor
Cedars-Sinai Medical Care Foundation
8700 Beverly Blvd, 
West Hollywood, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Omid Hamid is a Hematologist and an Oncologist in West Hollywood, California. Dr. Hamid is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Medulloblastoma.

His clinical research consists of co-authoring 211 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Metastatic Brain Tumor.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Saint John's Health Center
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

CEDARS-SINAI MEDICAL CARE FOUNDATION
8700 Beverly Blvd, West Hollywood, CA 90048
Other Locations
CEDARS-SINAI MEDICAL CARE FOUNDATION
2001 Santa Monica Blvd, Suite 560w, Santa Monica, CA 90404
CEDARS-SINAI MEDICAL CARE FOUNDATION
8635 W 3rd St, Suite 465w, Los Angeles, CA 90048
CEDARS-SINAI MEDICAL CARE FOUNDATION
2121 Santa Monica Blvd, Santa Monica, CA 90404
CEDARS-SINAI MEDICAL CARE FOUNDATION
11818 Wilshire Blvd, Los Angeles, CA 90025

Additional Areas of Focus

Dr. Hamid has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Enrollment Status: Recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab, TSR-022 Anti-TIM-3 Antibody, Carboplatin, Pemetrexed, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Tocilizumab
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Telatinib, Keytruda
Study Phase: Phase 2
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: CAB-ROR2-ADC
Study Phase: Phase 1/Phase 2
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Biological
Study Drug: Lifileucel
Study Phase: Phase 2
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Spartalizumab, LAG525, Capmatinib, Canakinumab, Ribociclib
Study Phase: Phase 2
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drugs: Vancomycin Pretreatment, Nivolumab, SER-401
Study Phase: Phase 1
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Drug
Study Drug: NC318
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug, Biological
Study Drugs: CART-TnMUC1, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: February 26, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Enrollment Status: Terminated
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 23 Less Clinical Trials

211 Total Publications

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology.
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology.
Journal: bioRxiv : the preprint server for biology
Published: August 01, 2025
Similar Doctors
Distinguished in Metastatic Brain Tumor
Dr. Jana L. Portnow
Oncology
Distinguished in Metastatic Brain Tumor
Dr. Jana L. Portnow
Oncology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (13.6 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jana Portnow is an Oncologist in South Pasadena, California. Dr. Portnow is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Endoscopy.

Advanced in Metastatic Brain Tumor
Dr. Edwin L. Jacobs
Oncology | Hematology
Advanced in Metastatic Brain Tumor
Dr. Edwin L. Jacobs
Oncology | Hematology
181 South Buena Vista Street, Floor 4, 
Burbank, CA 
 (6.5 miles away)
818-840-0921
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edwin Jacobs is a Hematologist and an Oncologist in Burbank, California. Dr. Jacobs is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Anal Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Jacobs is currently accepting new patients.

Distinguished in Metastatic Brain Tumor
Dr. Simon Khagi
Hematology Oncology | Hematology | Oncology
Distinguished in Metastatic Brain Tumor
Dr. Simon Khagi
Hematology Oncology | Hematology | Oncology

Hoag Clinic

1 Hoag Dr, 
Newport Beach, CA 
 (40.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Simon Khagi is a Hematologist Oncology specialist and a Hematologist in Newport Beach, California. Dr. Khagi is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hamid's expertise for a condition
ConditionClose
View All 66 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile